J. Safra Sarasin Holding AG Sells 105,453 Shares of Annexon, Inc. $ANNX

J. Safra Sarasin Holding AG reduced its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 47.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,768 shares of the company’s stock after selling 105,453 shares during the period. J. Safra Sarasin Holding AG’s holdings in Annexon were worth $591,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANNX. AQR Capital Management LLC increased its stake in shares of Annexon by 122.6% in the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company’s stock valued at $142,000 after purchasing an additional 40,637 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company’s stock worth $193,000 after buying an additional 7,553 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Annexon by 31.1% during the 1st quarter. Acadian Asset Management LLC now owns 203,990 shares of the company’s stock worth $393,000 after buying an additional 48,345 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Annexon by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company’s stock worth $5,484,000 after buying an additional 39,763 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Annexon by 6.6% in the second quarter. American Century Companies Inc. now owns 211,195 shares of the company’s stock valued at $507,000 after buying an additional 13,001 shares in the last quarter.

Annexon Stock Performance

Shares of ANNX opened at $5.50 on Friday. Annexon, Inc. has a 52 week low of $1.28 and a 52 week high of $7.18. The stock has a market capitalization of $657.97 million, a price-to-earnings ratio of -4.04 and a beta of 1.14. The stock has a fifty day moving average of $5.55 and a 200-day moving average of $4.57.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities analysts forecast that Annexon, Inc. will post -0.96 EPS for the current year.

Insider Transactions at Annexon

In other news, EVP Ted Yednock sold 7,857 shares of Annexon stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $5.11, for a total transaction of $40,149.27. Following the sale, the executive vice president directly owned 97,227 shares of the company’s stock, valued at approximately $496,829.97. This trade represents a 7.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William H. Carson purchased 8,000 shares of Annexon stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $5.67 per share, for a total transaction of $45,360.00. Following the completion of the acquisition, the director owned 62,405 shares of the company’s stock, valued at approximately $353,836.35. The trade was a 14.70% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders sold 32,513 shares of company stock valued at $165,973. 11.87% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ANNX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Chardan Capital restated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.00.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.